Chapter title |
Hybrid PET-MRI in Alzheimer’s Disease Research
|
---|---|
Chapter number | 12 |
Book title |
Biomarkers for Alzheimer’s Disease Drug Development
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-7704-8_12 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7703-1, 978-1-4939-7704-8
|
Authors |
Ismini C. Mainta, Maria I. Vargas, Sara Trombella, Giovanni B. Frisoni, Paul G. Unschuld, Valentina Garibotto |
Abstract |
Multiple factors, namely amyloid, tau, inflammation, metabolic, and perfusion changes, contribute to the cascade of neurodegeneration and functional decline occurring in Alzheimer's disease (AD). These molecular and cellular processes and related functional and morphological changes can be visualized in vivo by two imaging modalities, namely positron emission tomography (PET) and magnetic resonance imaging (MRI). These imaging biomarkers are now part of the diagnostic algorithm and of particular interest for patient stratification and targeted drug development.In this field the availability of hybrid PET/MR systems not only offers a comprehensive evaluation in a single imaging session, but also opens new possibilities for the integration of the two imaging information. Here, we cover the clinical protocols and practical details of FDG, amyloid, and tau PET/MR imaging as applied in our institutions. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 32 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 16% |
Student > Ph. D. Student | 3 | 9% |
Student > Bachelor | 3 | 9% |
Student > Master | 2 | 6% |
Lecturer | 1 | 3% |
Other | 3 | 9% |
Unknown | 15 | 47% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 25% |
Neuroscience | 3 | 9% |
Computer Science | 2 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Linguistics | 1 | 3% |
Other | 2 | 6% |
Unknown | 15 | 47% |